Immune-mediated anti-tumor effect

The \"immune-mediated anti-tumor effect\" refers to the ability of the host immune system—including T cells, NK cells, and antigen-presenting cells—to recognize and destroy tumor cells through mechanisms such as direct cytotoxicity, phagocytosis, and the presentation of tumor antigens leading to adaptive immune responses. This effect is leveraged therapeutically via immune checkpoint inhibitors, antibody-drug conjugates, adjuvants, and monoclonal antibodies, which either enhance immune cell function, promote tumor antigen release, or reduce immune suppression within the tumor microenvironment. These strategies can lead to tumor regression, the development of lasting anti-tumor immunity, and improved clinical outcomes for cancer patients[1][2][3][4][5][6]. This entry is not a canonical drug target (such as a named receptor, enzyme, or transporter), but a therapeutic outcome or immune mechanism relevant to cancer therapy.

Other names

Immunological anti-tumor effectImmune-mediated tumor killingImmunogenic tumor cell deathAdaptive and innate anti-tumor immunity

Enhancing T cell and NK cell activity against tumors[1][2][3][5] Stimulating dendritic cell maturation & antigen presentation[1][3] Inducing immunogenic tumor cell death and antigen release[1][5][3] Immune checkpoint blockade (removing inhibitory signals on T cells)[3] Fc-mediated antibody-dependent cellular cytotoxicity and phagocytosis[5] Metabolic reprogramming of T cells via AMPK activation (metformin)[4]